BRCA1 and breast carcinoma: Our findings support the use of mutational profiling of Chinese breast cancer patients with these characteristics to assess the presence of germline mutations in BRCA1/2 and other DDR pathway genes in order to identify patients who may benefit from treatment with PARP inhibitors.